Kidney International, Vol. 63 (2003), pp. 1044­1050
Blood lead and chronic kidney disease in the general
United States population: Results from NHANES III
PAUL MUNTNER, JIANG HE, SUMA VUPPUTURI, JOSEF CORESH, and VECIHI BATUMAN
Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine; Department of Medicine,
Tulane University School of Medicine, New Orleans, Louisiana; Department of Epidemiology, Biostatistics, and Medicine,
Johns Hopkins Medical Institutions, Baltimore, Maryland; and Epidemiology Branch, National Institute of Environmental
Health Sciences, Research Triangle Park, North Carolina
Blood lead and chronic kidney disease in the general United nonoccupational exposure to lead and a higher incidence
States population: Results from NHANES III. of nephropathy [2­6]. However, these studies involved
Background. High lead exposure is associated with hyper- relatively small numbers of patients. More recently,
tension and renal dysfunction but the effect of low-level envi-
large-scale epidemiologic studies have noted associations
ronmental exposure is not as well studied.
between environmental exposure to lead, even at low
Methods. We examined the association between blood lead
and renal function among a representative sample of the civil- levels, and higher serum creatinine [7­9]. However, none
ian noninstitutionalized United States population with and of these studies have been conducted among a represen-
without hypertension, age 20 years old or older, participating in tative sample of the general United States population.
the Third National Health and Nutrition Examination Survey
Although exact estimates vary, the prevalence of chronic
(NHANES III) (N  15,211). Elevated serum creatinine was
kidney disease (CKD) in the general United States popu-
defined as 99th percentile of each race-sex specific distribution
for healthy young adults and chronic kidney disease (CKD) as lation is high [10, 11]. In additional, renal insufficiency,
a glomerular filtration rate (GFR) 60 mL/min estimated using even prior to end-stage renal disease (ESRD), is associated
the Modification of Diet in Renal Disease (MDRD) formula. with several comorbidities, including anemia [12] and an
Results. Among persons with and without hypertension, mean
elevated risk of cardiovascular disease [13]. Despite a
blood lead was 4.21 and 3.30 ug/dL, respectively, the prevalence
high prevalence and concomitant risk of disease, the eti-
of elevated serum creatinine was 11.5% and 1.8%, respectively,
and CKD was 10.0% and 1.1%, respectively. Among persons with ologies of CKD have remained elusive [14, 15]. We exam-
hypertension, a graded association was present between higher ined the association between exposure to lead and CKD
quartile of blood lead and a higher odds ratio of both an ele- among the United States population using data from the
vated serum creatinine and CKD. Comparing the highest to
Third National Health and Nutrition Examination Sur-
lowest quartile of blood lead, the multivariate adjusted odds
vey (NHANES III).
ratio (95% CI) of an elevated serum creatinine and CKD were
2.41 (1.46, 3.97) and 2.60 (1.52, 4.45), respectively. The analo-
gous adjusted odds ratios (95% CI) among normotensives were
METHODS
1.09 (0.53, 2.22) and 1.09 (0.41, 2.89), respectively. Associations
were consistent when modeling lead as a continuous variable NHANES III was conducted from 1988 through 1994
and in all subgroups except smokers.
by the National Center for Health statistics [16]. NHANES
Conclusion. In the United States population with hyper-
III consisted of a standardized questionnaire adminis-
tension, exposure to lead, even at low levels, is associated with
CKD. Reduction of lead exposure may reduce the burden of tered in the home by a trained interviewer followed by
CKD in the community. a detailed physical examination at a Mobile Examination
Center (MEC). Participants were selected via a complex
sampling methodology with non-Hispanic African Ameri-
The nephrotoxic effects of lead were first noted over cans, Mexican Americans, the elderly, and children delib-
a century ago [1]. Since then, many studies have identi- erately over-sampled to achieve stable subpopulation
fied a strong association between both occupational and estimates. Overall, 18,825 adults, 20 years of age or older,
participated in NHANES III.
Data collected at the home interview relevant to the
Key words: chronic kidney disease, lead exposure, hypertension. current analysis included self-report of demographics
(age, race, and gender), education level attained, ciga-
Received for publication August 19, 2002
Accepted for publication October 11, 2002 rette smoking, household income, a history of diabetes,
and blood pressure medication usage. Three blood pres-
 2003 by the International Society of Nephrology
1044
Muntner et al: Blood lead and chronic kidney disease 1045
sure measurements were taken in the home and three a strong graded association was present between higher
at the MEC by a trained and certified observer following blood lead levels and a higher prevalence of elevated
the NHANES III study protocol. The average of all avail- serum creatinine and CKD. However, the effect of blood
able blood pressure measurements were used for data lead on elevated creatinine, estimated GFR, and CKD
analysis. Hypertension was defined as systolic blood was different for persons with and without hypertension
pressure 140 mmHg and/or diastolic blood pressure (all P interaction  0.001). Therefore, calculations were
90 mmHg and/or current use of antihypertensive medi- performed separately for persons with and without hy-
cations. pertension. Demographic distributions, mean levels of
Serum was collected at the MEC and creatinine levels blood lead, serum creatinine, and estimated GFR were
were measured by the modified kinetic Jaffe reaction determined for the study population. A quantile regres-
using a Hitachi 737 analyzer (Boehringer Mannheim sion model, including fifth-order polynomials of esti-
Corporation, Indianapolis, IN, USA) [17] and blood lead mated GFR and age, was used to determine the associa-
levels were determined using graphite furnace atomic tion of median (50th percentile) blood lead with estimated
absorption spetrophotometry. Two levels of quality con- GFR. Blood lead levels were divided into quartiles and
trol pools were used to ensure accurate blood lead mea- the prevalence of elevated serum creatinine and CKD
surement. The levels were chosen to reflect "low-nor- were determined. Next, the age, race and gender adjusted
mal" (5 g/dL) and "high-normal" blood lead level odds ratios of elevated serum creatinine and CKD were
(20 g/dL). The coefficient of variation was under 10% calculated by blood lead quartile and trends in the odds
for each of seven samples with a mean lead level ranging ratios across blood lead quartiles were assessed using
from 4.86 to 53.5 g/dL. the chi-squared test for trend. Odds ratios and trends
were also computed after additional adjustment for sys-
Outcome definition
tolic blood pressure, diabetes, household income, educa-
Two outcome measures were used in the current analy- tion level, health insurance, cigarette smoking, alcohol
sis: elevated serum creatinine and CKD. Because it has consumption, body mass index, and history of cardiovas-
been reported that non-Hispanic African Americans may
cular disease.
have a higher serum creatinine level at the same GFR
Associations using continuous blood lead levels were
as non-Hispanic Caucasians, we defined elevated serum
determined for all persons with and without hyperten-
creatinine using race-gender specific cut points of 1.5
sion and after further stratification by race-ethnicity (non-
mg/dL and 1.3 mg/dL for non-Hispanic Caucasian men
Hispanic Caucasians, non-Hispanic African Americans,
and women; 1.6 and 1.4 mg/dL for non-Hispanic Afri-
and Mexican Americans), gender, current cigarette smok-
can American men and women; and 1.4 and 1.2 mg/dL
ing, diabetes mellitus (fasting blood glucose 126 mg/dL)
for Mexican American men and women, respectively.
and household income ($20,000 and $20,000). Differ-
These cut points correspond to the 99th percentiles of the
ences across subgroups were assessed using tests for in-
race-gender specific serum creatinine distributions for
teraction. Due to its skewed distribution, blood lead was
healthy young men and women (age, 20 to 39 years old
log transformed for the continuous analyses. Odds ratios
without diabetes mellitus or hypertension) in this study.
are quoted for a twofold higher blood lead.
GFR was estimated by adjusting serum creatinine for
The survey weights provided in the NHANES III data
age, race, and sex using a formula proposed and validated
set were applied in all analyses to obtain United States
by the Modification of Diet in Renal Disease (MDRD)
population estimates. The svy commands in Stata 6.0
research group. [18] Specifically, GFR was estimated
were used to account for the complex survey design of
using the following formula:
NHANES III and obtain proper standard errors for all
Estimated GFR (mL/min/1.73 m2)  exp (5.228 estimates [21].
 1.154 * ln (creatinine)  0.299 (if female)
RESULTS
 0.192 (if African American)  0.203 * ln (age))
On average, compared to persons without hyperten-
Furthermore, serum creatinine was adjusted for dif-
sion, persons with hypertension were older (Table 1). In
ferences in calibration between the NHANES and MDRD
additional, a higher percentage of persons with hyperten-
laboratories as described previously [19]. CKD was de-
sion were non-Hispanic African Americans and a lower
fined as a GFR 60 mL/min/1.73 m2, the standard defini-
percentage were Mexican-Americans (Table 1). Mean
tion of CKD, as defined in the most recent Kidney Dis-
blood lead and serum creatinine were higher and esti-
ease Outcome Quality Initiative (KDOQI) guidelines [20].
mated GFR was lower for persons with hypertension.
Statistical methods Additionally, a greater proportion of participants with
hypertension had an elevated serum creatinine and CKD
Initial analyses were performed for persons with and
without hypertension pooled together. In these analyses, compared to persons without hypertension.
Muntner et al: Blood lead and chronic kidney disease
1046
Table 1. Demographic characteristics of the study populationa
Hypertension Normotension
(N  4813) (N  10,398) P value
Age grouping %
20­39 11.1 56.1
40­59 32.9 31.4
60­74 36.4 10.0
75 17.6 2.5 0.001
Non-Hispanic African
American % 13.5 10.5 0.001
Mexican American % 3.4 6.2 0.001
Male % 47.5 48.0 0.76
Blood lead lg/dL 4.21 (0.14) 3.30 (0.10) 0.001
Serum creatinine mg/dL 1.14 (0.01) 1.05 (0.004) 0.001
Estimated glomerular
filtration rate mL/min 95 (0.7) 115 (0.7) 0.001
Elevated serum
creatinineb % 11.5 1.8 0.001
Chronic kidney disease % 10.0 1.1 0.001
a Percentage or mean (standard deviation)
b Serum creatinine 1.5 and 1.3 mg/dL for non-Hispanic Caucasian men and
women, 1.6 and 1.4 for non-Hispanic African American men and women, and
1.4 and 1.2 for Mexican American men and women
After age adjustment, among persons with hyperten-
sion, higher blood lead level was associated with a lower
estimated GFR (Fig. 1A). This relationship was present
throughout the entire range of GFR among non-Hispanic
African Americans and Mexican Americans and was pres-
ent for non-Hispanic Caucasians with an estimated GFR
60 mL/min/1.73m2 (data not shown). The decrease in
estimated GFR associated with higher blood lead was
much less steep among persons without hypertension
(Fig. 1B).
The prevalence of elevated serum creatinine and CKD
were higher at higher blood lead quartiles among persons
with and without hypertension (Table 2). Among partici-
pants with hypertension, a graded association was pres-
ent between higher blood lead quartiles and a higher
prevalence of elevated serum creatinine and CKD after
adjustment for age, race, and gender (demographic ad-
justment) and further adjustment for diabetes, systolic
blood pressure, household income, education level, health
care coverage, and cigarette smoking (full adjustment). Fig. 1. Median (solid line) estimated glomerular filtration rate (GFR)
with 95% CI (dash lines) by blood lead level among the United States
After full adjustment, the odds ratio (95% CI) of ele-
population with hypertension (A) and without hypertension (B) ad-
vated serum creatinine and CKD in the highest com-
justed to 60 years of age.
pared to lowest quartile were 2.41 (1.46, 3.97) and 2.60
(1.52, 4.45), respectively. In contrast, after adjustment for
age, race, and gender, no association was present be-
tween blood lead quartile and prevalence of elevated elevated serum creatinine and CKD associated with two-
fold higher blood lead level were 1.07 (0.81, 1.41) and
serum creatinine or CKD among persons without hyper-
tension. Further adjustment did not alter this finding. 1.04 (0.72, 1.50), respectively.
For persons with hypertension, the association be-
Among persons with hypertension, each twofold higher
blood lead level was associated with an adjusted odds tween higher blood lead and an increased prevalence of
elevated serum creatinine and CKD was present among
ratio of elevated serum creatinine and CKD (95% CI) of
1.43 (1.20, 1.71) and 1.38 (1.15, 1.66), respectively (Ta- all subgroups except persons who currently smoked ciga-
rettes (Table 3). For non-Hispanic African Americans,
ble 3). In contrast, among persons without hypertension,
no association was present; the odds ratios (95% CI) of higher blood lead levels were associated with CKD [odds
Muntner et al: Blood lead and chronic kidney disease 1047
Table 2. Prevalence and odds ratios (95% CI) of chronic kidney disease by blood lead quartile and hypertension status,
among 13,141 NHANES III participants
Hypertension
Elevated serum creatinine Chronic kidney disease
Blood lead Odds ratioa Adjusted odds Odds ratioa Adjusted odds
(range, g/dL) % (95% CI) ratiob (95% CI) % (95% CI) ratiob (95% CI)
Quartile 1 (0.7 to 2.4) 7.2 1.00 1.00 6.1 1.00 1.00
Quartile 2 (2.5 to 3.8) 12.1 1.56 (1.04, 2.35) 1.47 (1.03, 2.10) 10.4 1.56 (1.02, 2.38) 1.44 (1.00, 2.09)
Quartile 3 (3.9 to 5.9) 12.4 1.68 (1.24, 2.26) 1.80 (1.34, 2.42) 10.8 1.69 (1.21, 2.33) 1.85 (1.32, 2.59)
Quartile 4 (6.0 to 56.0) 16.3 2.07 (1.26, 3.40) 2.41 (1.46, 3.97) 14.1 2.27 (1.31, 3.91) 2.60 (1.52, 4.45)
P trend 0.001 0.01 0.001 0.001 0.001 0.001
Normotension
Elevated serum creatinine Chronic kidney disease
Blood lead Odds ratioa Adjusted odds Odds ratioa Adjusted odds
(range, g/dL) % (95% CI) ratiob (95% CI) % (95% CI) ratiob (95% CI)
Quartile 1 (0.7 to 1.6) 1.1 1.00 1.00 0.4 1.00 1.00
Quartile 2 (1.7 to 2.8) 1.6 0.92 (0.48, 1.75) 1.11 (0.56, 2.21) 0.8 0.84 (0.35, 2.01) 0.90 (0.37, 2.16)
Quartile 3 (2.9 to 4.6) 2.2 1.04 (0.56, 1.94) 1.19 (0.62, 2.25) 1.3 1.03 (0.45, 2.33) 1.00 (0.45, 2.22)
Quartile 4 (4.7 to 52.9) 2.6 0.92 (0.50, 1.72) 1.09 (0.53, 2.22) 2.1 1.18 (0.50, 2.71) 1.09 (0.41, 2.89)
P trend 0.26 0.79 0.76 0.02 0.30 0.36
a Adjusted for age, race, and gender
b Adjustment for age, gender, systolic blood pressure, diabetes mellitus, current cigarette smoking, history of cardiovascular disease (myocardial infarction, stroke,
congestive heart failure), body mass index, alcohol consumption, household income, marital status, and health insurance
ratio (OR)  1.39; 95% CI, 1.10, 1.75], however, the The marked differences in the association between
blood lead levels and elevated creatinine and CKD for
association was not statistically significant for elevated
persons with and without hypertension were not unex-
serum creatinine (OR  1.21; 95% CI, 0.96, 1.52). A sig-
pected. Lead poisoning is a known cause of both hyper-
nificant interaction was present between cigarette smok-
tension and renal impairment and higher levels of lead
ing and blood lead; blood lead was associated with an
exposure may cause both hypertension and renal insuf-
increased risk of CKD among nonsmokers but not smok-
ficiency. However, not all previous studies found associa-
ers (P interaction  0.007 and 0.03 for elevated serum
tions between blood lead and blood pressure and there-
creatinine and CKD, respectively). Among the popula-
fore may not have explored the possible interaction of
tion without hypertension, elevated serum creatinine and
blood pressure, blood lead, and renal function [22, 23].
CKD were not associated with blood lead for any sub-
Given the high prevalence of hypertension among per-
groups except for persons with diabetes where higher
sons with CKD, the interaction of hypertension, blood
blood lead was associated with a higher prevalence of
lead, and CKD warrants further investigation in a pro-
CKD but not elevated serum creatinine.
spective cohort [11].
Occupational exposure to lead first occurred in ap-
DISCUSSION proximately 2500 bc and the first reports of the toxic
The results of the current analysis indicate that blood effects of such exposure were noted in 200 bc. However,
lead, even at low levels, is associated with an elevated the first report of the clinical nephrotoxicity of lead expo-
serum creatinine and CKD among persons with hyper- sure was by Lancereaux in 1862. During the late nine-
tension in the general United States population. These teenth and early twentieth century a large number of
associations were strong, dose-dependent and consistent reports on the association between high occupational
before and after comprehensive adjustment. These asso- exposure to lead and nephritis were reported. The fre-
ciations were present when evaluating blood lead as a quency of occupational exposure to lead during this time
continuous and categorical variable and evaluating renal made lead nephropathy a common diagnosis. The neph-
function using elevated creatinine and estimated GFR rotoxic effects of lead exposure were not limited to case
(i.e., CKD). In contrast, no association was present be- reports. In the first half of the twentieth century several
tween blood lead and either elevated serum creatinine epidemiologic mortality studies found increased renal
or CKD among persons without hypertension. This was disease mortality among occupational cohorts with high
apparent for the overall population without hyperten- lead exposures. Although there has been much debate
sion and within all subgroups except persons with dia- over the past 20 years regarding the relationship between
lead exposure and chronic renal failure, several studies
betes.
Muntner et al: Blood lead and chronic kidney disease
1048
Table 3. Adjusteda odds ratios (95% CI) of chronic kidney disease sons with a broad range of renal function and using cate-
associated with a twofold higher blood lead level
gorical outcomes should limit the misclassification of re-
for the overall population and by subgroup
nal function based on day-to-day variation in serum
Hypertension creatinine [27]. In additional, the results were consistent
Elevated creatinine Chronic kidney disease when assessing renal insufficiency as estimated GFR us-
Overall 1.43 (1.20, 1.72) 1.38 (1.15, 1.66) ing a validated formula from the MDRD study. Finally,
Non-Hispanic exposure to lead was assessed by blood lead. Although
Caucasians 1.49 (1.22, 1.83) 1.46 (1.19, 1.79)
there are better measurements of long-term environmen-
Non-Hispanic
African Americans 1.21 (0.96, 1.52) 1.39 (1.10, 1.75) tal lead exposure in individuals, the feasibility of their
Mexican Americans 2.13 (1.46, 3.11) 2.18 (1.48, 3.22) use was prohibitive given the large scale and broad scope
Males 1.71 (1.38, 2.12) 1.66 (1.31, 2.10)
of NHANES III [28, 29]. Blood lead is the most com-
Females 1.32 (1.06, 1.64) 1.38 (1.10, 1.75)
Nonsmokers 1.50 (1.24, 1.80) 1.53 (1.27, 1.86) monly used measure of environmental lead exposure in
Smokers 1.04 (0.70, 1.54) 0.88 (0.60, 1.30) population studies and the results of the current analysis
No diabetes 1.42 (1.15, 1.75) 1.43 (1.14, 1.79)
still provide strong data on the association between expo-
Diabetes 1.38 (1.00, 1.91) 1.44 (1.01, 2.05)
Income $20,000 1.39 (1.11, 1.74) 1.42 (1.12, 1.78) sure to lead and renal function. Furthermore, large popu-
Income $20,000 1.61 (1.27, 2.03) 1.60 (1.23, 2.10) lation studies indicate there exists a high correlation be-
No hypertension tween blood lead measurement and total body burden
Elevated creatinine Chronic kidney disease of lead as determined by the ethylenediaminetetraacetic
acid (EDTA)-lead mobilization test or x-ray fluores-
Overall 1.07 (0.81, 1.41) 1.04 (0.72, 1.38)
Non-Hispanic cence [4, 30].
Caucasians 1.08 (0.76, 1.54) 1.09 (0.69, 1.73) Results from the majority of studies suggest that higher
Non-Hispanic
blood lead levels are the cause, rather than the result, of
African Americans 1.05 (0.73, 1.52) 1.57 (0.68, 3.62)
Mexican Americans 0.85 (0.39, 1.86) 1.23 (0.40, 3.75) lower renal function [3­5, 31]. For example, in an Austra-
Males 1.06 (0.69, 1.65) 1.32 (0.80, 1.34) lian study among individuals with no reported history of
Females 1.01 (0.74, 1.39) 0.81 (0.49, 1.34)
heavy lead exposure, there were no differences in blood
Nonsmokers 1.09 (0.81, 1.46) 1.13 (0.72, 1.76)
Smokers 0.91 (0.52, 1.60) 0.85 (0.43, 1.68) lead levels in those with normal renal function, or mild
No diabetes 1.07 (0.79, 1.45) 1.06 (0.69, 1.65) or severe renal dysfunction. In contrast, blood lead con-
Diabetes 1.26 (0.59, 2.68) 2.82 (1.05, 7.59)
centrations were higher among adults with renal failure
Income $20,000 0.93 (0.67, 1.30) 0.89 (0.63, 1.26)
Income $20,000 1.13 (0.77, 1.66) 1.31 (0.71, 2.41) and a history of childhood lead poisoning [31]. Other
a Adjustment for age, gender, systolic blood pressure, diabetes mellitus, current studies provide data that support the hypothesis that
cigarette smoking, history of cardiovascular disease (myocardial infarction, renal function does not alter blood lead levels [3, 32].
stroke, congestive heart failure), body mass index, alcohol consumption, house-
hold income, marital status, and health insurance The less steep decrease in GFR associated with higher
blood lead in persons without hypertension (Fig. 1B)
further confirms the premise that renal function per se
does not cause increased blood lead level.
have found a higher incidence of ESRD among persons Although previous studies have investigated the asso-
with high levels of lead exposure. Recent epidemiologic ciation between lead exposure and renal function prior
studies have expanded the exploration for clues into the to ESRD, there are several aspects of the current study
relationship between lead and renal failure to study the that make it unique. The current analysis provides data
effects of low-level environmental lead exposure and that is representative of the general noninstitutionalized
renal insufficiency, prior to ESRD. Studies, both cross- United States population. Most previous studies of lead
sectional and cohort studies, performed over the past 25 exposure have focused on groups with high-exposure
years have found associations between elevated blood levels. While the Normative Aging Study evaluated the
lead levels and reduced renal function. effect of low levels of blood lead and renal function in
Although the overall results of the current study are the United States population, this study was limited to
generally consistent with previous studies, some limita- men, 97% of whom were Caucasian, and consisted of a
tions in the methodology we applied deserve mention. smaller sample size (N  744) compared to the current
First, NHANES III is a cross-sectional survey. The lack study (N  15,211) [33]. Although data from NHANES II
of prospective follow-up limits the ability to make infer- was used to study the association between blood lead
ences regarding the causality of the associations detected and blood pressure, no interaction between blood lead,
[24]. Second, serum creatinine is a relatively crude mea- blood pressure, and kidney function was found [34]. Fi-
sure of renal function [25, 26]. Due to substantial intra- nally, investigators from the Cadmibel Study found an
personal variability associated with serum creatinine, association between blood lead and renal function in
analyses relied upon categorical outcomes (i.e., elevated the general population of Belgium [8]. In contrast, no
association was present between blood lead and blood
creatinine and CKD). The current study included per-
Muntner et al: Blood lead and chronic kidney disease 1049
7. Lin JL, Tan DT, Hsu KH, Yu CC: Environmental lead expo-
pressure in that study, and the presence of an interaction
sure and progressive renal insufficiency. Arch Intern Med 161:264­
between blood lead, blood pressure, and kidney function
271, 2001
was not reported [23]. 8. Staessen JA, Lauwerys RR, Buchet JP, et al: Impairment of
renal function with increasing blood lead concentrations in the
An additional strength of the current analysis is that
general population. The Cadmibel Study Group. N Engl J Med
several potential confounders were collected as part of
327:151­156, 1992
NHANES III for which we were able to adjust. The com- 9. Kim R, Hu H, Rotnitzky A, et al: Longitudinal relationship be-
prehensive nature of data collection in NHANES III tween dentin lead levels in childhood and bone lead levels in young
adulthood. Arch Environ Health 51:375­382, 1996
enabled us to determine the independent nature of the
10. Jones CA, McQuillan GM, Kusek JW, et al: Serum creatinine
association between blood lead and renal function. Also,
levels in the US population: Third National Health and Nutrition
the broad number of covariates collected in NHANES Examination Survey. Am J Kidney Dis 32:992­999, 1998
11. Coresh J, Wei GL, McQuillan G, et al: Prevalence of high blood
III allowed us to estimate GFR using the abbreviated
pressure and elevated serum creatinine level in the United States:
MDRD formula. This method of estimating GFR has
Findings from the third National Health and Nutrition Examina-
been validated and the serum creatinine in NHANES tion Survey (1988­1994). Arch Intern Med 161:1207­1216, 2001
III was calibrated specifically for use of this formula [19]. 12. Astor BC, Muntner P, Levin A, et al: Association of kidney func-
tionwithanemia:TheThird NationalHealthandNutritionExamina-
The consistency of the relationships detected using both
tion Survey (1988­1994). Arch Intern Med 162:1401­1408, 2002
elevated creatinine and low GFR as outcomes, even after
13. Muntner P, He J, Hamm L, et al: Renal insufficiency and subse-
adjustment for several confounders, provides confidence quent death resulting from cardiovascular disease in the United
States. J Am Soc Nephrol 13:745­753, 2002
in the results of the current study. Finally, because little
14. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of car-
is known about the causes of renal insufficiency, the
diovascular disease in chronic renal disease. Am J Kidney Dis 32:
current study provides important data that can be used
S112­S119, 1998
in designing future studies of renal disease. 15. Perneger TV, Brancati FL, Whelton PK, Klag MJ: Studying
the causes of kidney disease in humans: A review of methodologic
Since NHANES II, the blood lead concentrations have
obstacles and possible solutions. Am J Kidney Dis 25:722­731, 1995
declined dramatically in the United States population
16. National Center for Health Statistics: Plan and operation of
[35­37]. For example, among the United States popula- the Third National Health and Nutrition Examination Survey,
tion aged 1 to 74 years, mean blood lead concentrations 1988­1994, Washington, DC, United States Department of Health
and Human Services Publication 1:94­1308, 1994
dropped by 78% from 12.8 during NHANES II (1976
17. Kasiske B, Keane W: Laboratory assessment of renal disease:
to 1980) to 2.8 during the first phase of NHANES III
Clearance, urinalysis, and renal biopsy, in The Kidney, 6th edition,
(1988 to1991). However, our results indicate that even edited by Brenner B, Rector F, 2000, pp 1137­1174
18. Levey AS, Bosch JP, Lewis JB, et al: A more accurate method
the low levels of lead that people are still exposed may
to estimate glomerular filtration rate from serum creatinine: A
not be without detrimental health effects. The decline
new prediction equation. Modification of Diet in Renal Disease
in environmental exposure to lead has been reported to
Study Group. Ann Intern Med 130:461­470, 1999
be primarily the result of removal of lead from gasoline 19. Coresh J, Astor BC, McQuillan G, et al: Calibration and random
variation of the serum creatinine assay as critical elements of using
and soldered cans. Although the cross-sectional nature
equations to estimate glomerular filtration rate. Am J Kidney Dis
of the current study limits the inferences that can be
39:920­929, 2002
made based on the current results, given the potential 20. KDOQI Working Group: Definition and classification of stages
benefits of lead removal, reducing environmental lead of chronic kidney disease. Am J Kidney Dis 39:S46­S75, 2002
21. StataCorp: STATA Statistical Software. Release 6.0, STATA Cor-
exposure may provide substantial benefits in reducing
poration, College Station, TX, 1999
the burden of hypertension and CKD.
22. Staessen JA, Bulpitt CJ, Fagard R, et al: Hypertension caused
by low-level lead exposure: Myth or fact? J Cardiovasc Risk 1:87­
Reprint requests to Paul Muntner, Ph.D., Department of Epidemiol-
97, 1994
ogy, Tulane University SPHTM, 1430 Tulane Avenue, SL-18, New
23. Staessen JA, Roels H, Fagard R: Lead exposure and conven-
Orleans, LA 70112, USA.
tional and ambulatory blood pressure: A prospective population
E-mail: pmuntner@tulane.edu
study. PheeCad Investigators. JAMA 275:1563­1570, 1996
24. Hill AB: The environment and disease: Association or causation?
REFERENCES Proc R Soc Med 58:295­300, 1965
25. Levey AS, Bosch JP, Lewis JB, et al: A more accurate method
1. Lanceraux E: Nephrite et arthrite saturnines: Coincidence de ces
to estimate glomerular filtration rate from serum creatinine: A new
affections: Parallele avec la nephrite et l'arthrite gouteusses. Acrh
prediction equation. Ann Intern Med 130:877­884, 1999
de Gereales Medicines 6:641­647, 1881
26. Perrone R, Madias N, Levey A: Serum creatinine as an index of
2. Bernard BP, Becker CE: Environmental lead exposure and the
renal function: New insights into old concepts. Clin Chem 38:1933­
kidney. J Toxicol Clin Toxicol 26:1­34, 1988
1953, 1992
3. Batuman V, Maesaka JK, Haddad B, et al: The role of lead in
27. Szklo M, Nieto FJ: Understanding the lack of validity: Bias, in
gout nephropathy. N Engl J Med 304:520­523, 1981
Epidemiology: Beyond the Basics, Gaithersburg, MD, Aspen Pub-
4. Batuman V: Lead nephropathy, gout, and hypertension. Am J
lishers, Inc., 1999, pp 125­169
Med Sci 305:241­247, 1993
28. Hu H, Hashimoto D, Besser M: Levels of lead in blood and bone
5. Batuman V, Landy E, Maesaka JK, Wedeen RP: Contribution
of women giving birth in a Boston hospital. Arch Environ Health
of lead to hypertension with renal impairment. N Engl J Med 309:
51:52­58, 1996
17­21, 1983
29. Hu H, Watanabe H, Payton M, et al: The relationship between
6. Wedeen RP, Maesaka JK, Weiner B, et al: Occupational lead
nephropathy. Am J Med 59:630­641, 1975 bone lead and hemoglobin. JAMA 272:1512­1517, 1994
Muntner et al: Blood lead and chronic kidney disease
1050
30. Loghman-Adham M: Renal effects of environmental and occupa- blood pressure. Relationship in the adolescent and adult US popu-
lation. JAMA 253:530­534, 1985
tional lead exposure. Environ Health Perspect 105:928­939, 1997
31. Emmerson BT: Lead stores in patients with renal insufficiency. 35. Pirkle JL, Brody DJ, Gunter EW, et al: The decline in blood
lead levels in the United States. The National Health and Nutrition
Nephron 58:233­234, 1991
32. Batuman V, Wedeen RP, Bogden JD, et al: Reducing bone lead Examination Surveys (NHANES). JAMA 272:284­291, 1994
36. Annest JL, Pirkle JL, Makuc D, et al: Chronological trend in
content by chelation treatment in chronic lead poisoning: An in
vivo x-ray fluorescence and bone biopsy study. Environ Res 48:70­ blood lead levels between 1976 and 1980. N Engl J Med 308:1373­
1377, 1983
75, 1989
33. Payton M, Hu H, Sparrow D, Weiss ST: Low-level lead exposure 37. Brody DJ, Pirkle JL, Kramer RA, et al: Blood lead levels in the
US population. Phase 1 of the Third National Health and Nutrition
and renal function in the Normative Aging Study. Am J Epidemiol
140:821­829, 1994 Examination Survey (NHANES III, 1988 to 1991). JAMA 272:277­
283, 1994
34. Harlan WR, Landis JR, Schmouder RL, et al: Blood lead and
